Hospital General Universitario Morales Meseguer

The department at Hospital General Universitario Morales Meseguer conducts extensive research on blood‑related cancers, aiming to improve treatment outcomes and explore novel therapeutic combinations. Current studies focus on multiple myeloma and acute myeloid leukemia.

• Evaluation of new antibody‑drug conjugates in multiple myeloma
• Comparative studies of targeted kinase inhibitors for chronic myelogenous leukemia
• Trials assessing combination regimens in diffuse large B‑cell lymphoma
• Investigation of novel immunotherapies for acute myeloid leukemia

With 85 active trials and a strong investigator team, the department seeks to bring effective, less toxic options to patients with hematologic cancers.

Research focuses on disorders where the immune system attacks blood cells, testing therapies that restore normal counts and reduce dependence on steroids. Studies include romiplostim combined with dexamethasone and the use of ianalumab for warm autoimmune hemolytic anemia.

• Safety and efficacy of romiplostim plus dexamethasone in primary immune thrombocytopenia
• Evaluation of ianalumab for durable hemoglobin response in warm autoimmune hemolytic anemia
• Study of povetacicept in patients with autoimmune cytopenias
• Comparison of standard care versus novel agents in immune thrombocytopenia

These trials aim to provide lasting remission and improve quality of life for patients with chronic immune‑driven blood disorders.

A broad portfolio of studies targets hormone‑receptor positive, HER2‑negative and triple‑negative breast cancers, evaluating new targeted agents and combination strategies. The work includes ribociclib added to endocrine therapy and inavolisib with HER2‑targeted treatment.

• Adding ribociclib to endocrine therapy in early HR+/HER2‑negative disease
• Testing inavolisib with HER2‑targeted therapy in PIK3CA‑mutant tumors
• Comparing trastuzumab deruxtecan versus trastuzumab emtansine in high‑risk HER2‑positive disease
• Assessing fezolinetant for relief of vasomotor symptoms during endocrine treatment

The goal is to increase disease‑free survival while managing treatment‑related side effects for diverse breast cancer subtypes.

Clinical trials address both non‑small cell lung cancer and related thoracic conditions, focusing on targeted therapies and immunotherapy combinations. Investigations feature osimertinib plus chemotherapy and novel anti‑PD‑L1 regimens.

• Comparing osimertinib plus chemotherapy versus chemotherapy alone in NSCLC
• Evaluating anti‑PD‑L1 therapy combined with chemotherapy in metastatic NSCLC
• Investigating the role of supplemental oxygen in acute pulmonary embolism management
• Study of ociperlimab with tislelizumab versus pembrolizumab in PD‑L1‑selected NSCLC

These studies aim to extend survival and improve symptom control for patients with advanced lung disease.

Trials explore innovative treatments for gastric, pancreatic, and neuroendocrine tumors, integrating targeted agents with standard chemotherapy. Notable agents include bemarituzumab for FGFR2b‑positive gastric cancer and cam2029 for metastatic neuroendocrine tumors.

• Evaluating bemarituzumab plus mFOLFOX6 in FGFR2b‑positive gastric cancer
• Assessing cam2029 versus octreotide in metastatic gastroenteropancreatic neuroendocrine tumors
• Testing ABTL0812 combined with FOLFIRINOX in metastatic pancreatic adenocarcinoma
• Comparing sacituzumab govitecan with physician’s choice in triple‑negative breast cancer with gastrointestinal involvement

The research seeks to improve progression‑free survival and offer new options for patients with difficult‑to‑treat gastrointestinal malignancies.

Focused studies investigate prevention and treatment of complications after allogeneic stem cell transplantation, including immune modulation and infection control. Projects evaluate alpha‑1 antitrypsin for acute GVHD prevention and strategies against cytomegalovirus reactivation.

• Assessing alpha‑1 antitrypsin for prevention of acute GVHD
• Monitoring cytomegalovirus infection post‑transplant with prophylactic strategies
• Evaluating novel agents for treatment‑resistant gastrointestinal acute GVHD
• Comparing outcomes of different conditioning regimens in hematopoietic cell transplantation

These efforts aim to reduce transplant‑related mortality and enhance long‑term graft function for patients undergoing hematopoietic stem cell transplantation.